Denis Corin, CEO, of Q BioMed Inc. Provides Key Updates and Outlook in a New Audio Interview with SmallCapVoice.com
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (OTCQB: QBIO) (the "Company"), a commercial stage biotechnology company, announced today that a new
audio interview with the Company is now available.
The interview featuring an overview of QBIO’s current news and moves can be heard at https://www.smallcapvoice.com/interview-q-biomed-qbio/
Denis Corin, CEO of Q BioMed Inc., called back in to SmallCapVoice.com for a follow up interview to discuss the recent news and events for the Company. Early in the coronavirus saga, that would
evolve into a global health pandemic, QBIO made a major announcement about the work being done along with its research partner Mannin Research Inc. The combined efforts of the two companies was to
develop a potential adjunct treatment for various infectious diseases like the coronavirus. Recent news highlighted the urgency for the rapid development of novel drugs for the treatment of
life-threatening complications caused by COVID-19 and other viral infections. Corin gives an update as well as an overall overview of QBIO’s work in this area.
In addition to the work the Company has been doing in its core markets, QBIO has also announced a key financing and restructuring of debt. Corin stated: “Q BioMed Inc. has been around roughly five
years and I am thrilled with the progress that we have made over those years. We are now in a revenue generating state. We are looking at our next steps with regards to commercialization of our
Strontium89 drug coupled with our desire to list on the NASDAQ as quickly as possible. Making this the right time to work on our balance sheet and eliminate as much debt as possible. We worked
with a trusted partner and converted out about $4,000,000 of debt into equity. This also allowed to fund our current operations and pipeline of key assets.”
Please visit http://www.QBioMed.com and sign up for regular updates.
About Q BioMed Inc.
Lesen Sie auch
Q BioMed Inc. is a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need.